Why carry out the study?

Botulinum toxin serotype A (BoNT/A) is widely used for minimal invasive aesthetic treatments, and the different brands currently available exhibit structural variations.

We assessed the efficacy of different BoNT/A formulations available in the marke, with a specific emphasis on their capacity to reduce bite force and treat wrinkles.

What was learned from this study?

A significant decrease in bite force was noted within 2–4 weeks post-injection, with the PraboA formulation exhibiting the most substantial impact, although no statistically significant differences were observed among the different BoNT/A formulations.

The reduction in bite force was temporary, returning to baseline levels 4 months post-injection. Nonetheless, over half of the participants maintained improved bite force beyond the 16-week period.

Despite the structural variations among the BoNT/A formulations, these differences did not result in significant differences in the duration or effectiveness of reducing bite force and treating wrinkles.